# Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

> **NCT06449222** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BioNTech SE** · enrollment: 83 (actual)

## Conditions studied

- Locally Advanced Breast Cancer
- Triple Negative Breast Cancer
- Metastatic Triple Negative Breast Cancers

## Interventions

- **DRUG:** BNT327 Dose Level 1 (DL1)
- **DRUG:** BNT327 Dose Level 1 (DL2)
- **DRUG:** Nab-placlitaxel
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **DRUG:** Paclitaxel
- **DRUG:** Eribulin
- **DRUG:** BNT327 Optimized Dose
- **DRUG:** BNT327 Equivalent Q3W Dose

## Key facts

- **NCT ID:** NCT06449222
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-26
- **Primary completion:** 2028-08
- **Final completion:** 2029-06
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06449222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06449222, "Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06449222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*